Sector: MedicalCytRx Corporation (NASDAQ: CYTR)
Headlines
- Pending Key Developments Ahead for CytRx Corporation (NASDAQ: CYTR)
Nov 23, 2009 10:39 AM | CYTR
- Technical Breakout Alert Issued For CytRx (NASDAQ:CYTR)
Nov 23, 2009 10:02 AM | ACUS, ALXN, AMGN, CYTR, DSCO, MDCO
- CytRx to Initiate Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Gastric Cancer
Nov 18, 2009 08:30 AM | CYTR
- CytRx Reports 2009 Third Quarter Financial Results
Nov 09, 2009 08:30 AM | CYTR
- CytRx Announces Publication of Paper Stating that Chaperone Amplification Represents a 'Significant Strategy' in Anti-aging Pharmaceutical Design
Oct 28, 2009 08:30 AM | CYTR
- CytRx Fortifies Executive Suite with Addition of Chief Medical Officer
Oct 13, 2009 08:30 AM | CYTR, PDLI
- CytRx and Cephalon Oncology Therapies to be Evaluated as Treatment for Relapsed Acute Promyelocytic Leukemia
Sep 14, 2009 08:30 AM | CEPH, CYTR
- CytRx Secures Key European Patent for Arimoclomol
Sep 10, 2009 08:30 AM | CYTR
- CytRx to Present at the Sachs Associates Annual Biotech in Europe Investor Forum
Sep 09, 2009 08:30 AM | CYTR
- CytRx Receives FDA Letter Regarding Arimoclomol Phase IIb Clinical Trial for ALS
Sep 08, 2009 08:30 AM | CYTR
- CytRx Reports 2009 Second Quarter Financial Results
Aug 10, 2009 08:33 AM | CYTR
- CytRx to Receive FDA Correspondence Regarding Clinical Development of Arimoclomol in ALS
Aug 06, 2009 08:35 AM | CYTR
- CytRx Drug Candidate INNO-206 Results in Ovarian Tumor Shrinkage in Animal Trials
Jul 28, 2009 08:36 AM | CYTR
- CytRx Announces Compliance with NASDAQ’s Minimum Bid Requirement
Jul 27, 2009 08:35 AM | CYTR
- CytRx Announces $20 Million Registered Direct Offering
Jul 24, 2009 02:01 PM | CYTR
- CytRx's Tamibarotene Receives Positive Opinion from the Committee for Orphan Medicinal Products in the European Union for Treatment of APL
Jul 24, 2009 08:31 AM | CYTR
- CytRx’s INNO-206 Significantly Inhibits Pancreatic Cancer Growth in Animal Trials
Jul 20, 2009 08:32 AM | CYTR
- CytRx’s INNO-206 Demonstrates Statistically Significant Tumor Shrinkage in Animal Trial for Breast Cancer
Jul 13, 2009 08:37 AM | CYTR
- CytRx Files Report with the FDA in Response to the Partial Clinical Hold on its Phase 2b Arimoclomol ALS Trial
Jun 30, 2009 08:43 AM | CYTR
- CytRx Reports Favorable Progress Update for Its Pivotal Phase 2 Clinical Trial with Tamibarotene as a Third-line Treatment for Acute Promyelocytic Leukemia
Jun 29, 2009 08:43 AM | CYTR
- Form 3 LEVITT DANIEL J For: Oct 12 (10K)
Oct 14, 2009 07:06 PM
- Form 4 Barber Jack R For: Jul 01 (10K)
Jul 06, 2009 05:02 PM
- Form 4 CALOZ JOHN Y For: Jan 02 (10K)
Jan 06, 2009 03:08 PM
- Form 4 FOGELMAN MITCHELL K For: Nov 21 (10K)
Nov 24, 2008 08:53 PM
- Form 4 CALOZ JOHN Y For: Nov 21 (10K)
Nov 24, 2008 08:45 PM
- Form 4 Ng Shi Chung For: Nov 21 (10K)
Nov 24, 2008 08:30 PM
- Form 4 Levin Ben For: Nov 21 (10K)
Nov 24, 2008 07:07 PM
- Form 4 Barber Jack R For: Nov 21 (10K)
Nov 24, 2008 06:58 PM
- Form 4 KRIEGSMAN STEVEN A For: Nov 21 (10K)
Nov 24, 2008 06:40 PM
- Form 3 Wieland Douglas Scott For: Nov 21 (10K)
Nov 24, 2008 06:24 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
CYTR
|
Compare to S&P
|
| YTD |
280.00 %
|
214.50 %
|
| 4 Weeks |
26.67 %
|
25.30 %
|
| 12 Weeks |
12.87 %
|
6.41 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 300.00 %
|
|
EPS Growth in Last Year: 233.33 %
|
|
Sales Growth in Last Quarter: 621.37 %
|
|
Sales Growth in Last Quarter: 658.34 %
|
|
